Anidulafungin Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ADOPT)
Ключови думи
Резюме
Описание
All obese patients with a BMI ≥ 40 kg/m2 undergoing endoscopic gastric bypass surgery who receive a prophylactic single dose of 100 mg anidulafungin will be included in the analysis. A PK curve will be determined after administration of anidulafungin at t=0.5, 1, end of infusion, 2, 4, 6, 8, 10, 12, 24, and 48 and (if feasible) 72 hours post infusion (n=12 samples). Blood samples (4 mL) on PK days will be taken to obtain at least 2.0 mL of plasma.
Дати
Последна проверка: | 09/30/2014 |
Първо изпратено: | 11/28/2013 |
Очаквано записване подадено: | 12/18/2013 |
Първо публикувано: | 12/26/2013 |
Изпратена последна актуализация: | 10/26/2014 |
Последна актуализация публикувана: | 10/27/2014 |
Действителна начална дата на проучването: | 07/31/2014 |
Приблизителна дата на първично завършване: | 09/30/2014 |
Очаквана дата на завършване на проучването: | 09/30/2014 |
Състояние или заболяване
Интервенция / лечение
Drug: Anidulafungin 100 mg single dose
Фаза
Групи за ръце
Arm | Интервенция / лечение |
---|---|
Experimental: Anidulafungin 100 mg single dose 100 mg single dose anidulafungin pre-surgery (gastric bypass) | Drug: Anidulafungin 100 mg single dose Anidulafungin 100mg single dose iv pre-surgery (gastric bypass) |
Критерии за допустимост
Възрасти, отговарящи на условията за проучване | 18 Years Да се 18 Years |
Полове, допустими за проучване | All |
Приема здрави доброволци | Да |
Критерии | Inclusion Criteria: 1. Patient has a BMI ≥40 kg/m2 and is undergoing endoscopic gastric bypass surgery. 2. Subject is at least 18 years of age on the day of screening. 3. If subject is female: neither pregnant, nor able to become pregnant and is not nursing an infant. 4. Subject or legal representatives are able and willing to sign the Informed Consent before screening evaluations. Exclusion Criteria: 1. Documented history of sensitivity to medicinal products or excipients similar to those found in the echinocandin preparation. 2. History of, or current abuse of drugs, alcohol or solvents. 3. Inability to understand the nature of the trial and the procedures required. |
Резултат
Първични изходни мерки
1. anidulafungin area under the curve [0-72 h after single dose]
Вторични изходни мерки
1. Predict long-term exposure after repeated dosing by using a pharmacokinetic model of anidulafunign in obese patients by using AUC(0-inf), Cmax, elimination half-life and clearance. [PK curve on day 1-3]
Други изходни мерки
1. adverse events [0-72 h after dosing]